<DOC>
	<DOCNO>NCT00050427</DOCNO>
	<brief_summary>The purpose study test safety effectiveness investigational chemotherapy agent patient advance breast cancer .</brief_summary>
	<brief_title>A Study ET-743 ( Trabectedin ) Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>Patients enrol study study specific-entry criterion meet informed consent obtain . Patients required attend regular clinic visit receive study medication status monitor . Patients also require radiologic tumor assessment perform multiple time throughout study . A detailed explanation provide study physician ( Investigator ) conduct study . Trabectedin 580 mcg/m2 weekly 3 consecutive week ( Treatment A ) 1,300 mcg/m2 every 21 day ( Treatment B ) give patient 3-hour intravenous ( i.v ) . infusion via central venous catheter tube place large vein use administer medication . All patient give dexamethasone 10 mg i.v . 30 minute trabectedin infusion . Patients may receive multiple cycle trabectedin absence disease progression .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Breast Diseases</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antineoplastic Agents , Alkylating</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Diagnosis advance breast cancer Prior therapy anthracycline taxane ( 2 type chemotherapy drug ) At least one measureable tumor lesion Adequate bone marrow , hepatic renal function Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Known hypersensitivity component i.v . formulation ET743 dexamethasone Pregnant lactate woman Known metastasis ( spread ) cancer central nervous system History another neoplastic disease unless remission five year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Trabectedin</keyword>
	<keyword>Yondelis</keyword>
	<keyword>ET743</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Breast</keyword>
	<keyword>Cancer</keyword>
	<keyword>Antineoplastic Agents , Alkylating Agents</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
</DOC>